In this initial clinical study, radiofrequency tags were safe and able to successfully localize nonpalpable breast lesions. Radiofrequency identification technology may represent an alternative method to hook wire localization.

Male breast cancer is rare, comprising less than 1% of all breast cancers (1). In 2015, only 2,350 new cases of breast cancer are expected to be diagnosed in men (2). Although the overall prognosis for male breast cancer is similar to that for females, the diagnosis is often made at later stages (3). This is thought to be due to several factors, including the absence of breast cancer screening in men.Breast cancer screening would not be advantageous for men at average risk given the rarity of the disease (1). However, there may be a subset of men with elevated risk who might benefit from periodic clinical breast examination (CBE) and possibly annual screening mammography. We report two cases of breast cancer in men with moderate risk factors to highlight potential gaps in screening guidelines.A 51-year-old African-American male-to-female transsexual presented with a self-detected right breast palpable lump. At age 2, the patient underwent bilateral orchiectomy for undescended testes. She reported using estrogen injections since age 14. Her family history was significant for a maternal grandmother and aunt with breast cancer. Examination confirmed periareolar nodularity without adenopathy. Mammography revealed suspicious microcalcifications. Stereotactic-guided core biopsy yielded ductal carcinoma in situ (DCIS) with intermediate nuclear grade and comedonecrosis. The patient underwent bilateral skin sparing mastectomies and right sentinel lymph node biopsy. Final pathology showed multifocal DCIS and a 1 cm focus of moderately differentiated invasive ductal carcinoma with negative margins and sentinel nodes, Stage IA (pT1bN0M0). The tumor was negative for both hormone receptors and human epidermal growth factor receptor 2 (HER2)/neu. Adjuvant chemotherapy was recommended, and she was advised to discontinue estrogen therapy. The patient tested negative for a BRCA mutation.A 44-year-old African-American male with 47XXY Klinefelter syndrome (KS) presented with a left breast mass, and a history of bilateral gynecomastia. He had no contributory family history. Examination revealed a retroareolar left breast mass, without adenopathy. Genital exam was significant for bilateral atrophic testes. A corresponding spiculated mass was visualized on mammography, and ultrasound showed a hypoechoic mass with irregular margins. Core needle biopsy revealed moderately differentiated infiltrating ductal carcinoma that was strongly hormone receptor positive and HER2/neu negative. The patient underwent left simple mastectomy with sentinel lymph node biopsy and concurrent completion axillary dissection after nodal metastasis was evident on frozen section. Final pathology showed moderately differentiated infiltrating ductal carcinoma, with metastasis to one of 18 nodes, Stage IIB (pT2N1M0). He underwent adjuvant chemo-and radiotherapy, as well as antiestrogen therapy.There are several risk factors for the development of breast cancer in men. The most significant of these is a mutation in the BRCA tumor suppressor genes, with BRCA2 mutatio...

Lymphoepithelioma-like carcinoma of the breast is a rare malignancy, with fewer than 20 cases documented in the literature. Given the paucity of reported cases, there is limited information available to guide the diagnosis and management of patients with this tumor. We present a case of a 39-year-old woman with a palpable right breast mass that was initially diagnosed by core needle biopsy as infiltrating carcinoma with prominent lymphoplasmacytic stroma. Subsequent neoadjuvant chemotherapy with docetaxel, doxorubicin, and cyclophosphamide resulted in a marked decrease in the size of the mass. After wide local surgical excision, pathology revealed a lymphoepithelioma-like carcinoma of the breast. Given the excellent treatment response, our experience may help clinicians determine future therapeutic strategies for this rare breast tumor.